Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price dropped 14.5% on Tuesday . The company traded as low as C$0.27 and last traded at C$0.27. Approximately 438,482 shares traded hands during trading, a decline of 36% from the average daily volume of 690,023 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Down 14.5 %
The business has a 50-day moving average price of C$0.11 and a two-hundred day moving average price of C$0.08. The company has a market capitalization of C$23.09 million, a price-to-earnings ratio of -13.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What Investors Need to Know About Upcoming IPOs
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Canadian Penny Stocks: Can They Make You Rich?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- The 3 Best Fintech Stocks to Buy Now
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
